{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:40:48Z","timestamp":1794256848262,"version":"4.9.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":681,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41379-020-00695-5","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T10:07:20Z","timestamp":1603102040000},"page":"603-612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays"],"prefix":"10.1016","volume":"34","author":[{"given":"Carrie L.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-2961","authenticated-orcid":false,"given":"Beth T.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra H.","family":"Ligon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3769-0247","authenticated-orcid":false,"given":"Fei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Maffeis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa R.","family":"Nucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7631-6525","authenticated-orcid":false,"given":"David L.","family":"Kolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-020-00695-5_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1038\/s41379-020-00695-5_bib2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1158\/1055-9965.EPI-15-0316","article-title":"The growing burden of endometrial cancer: a major racial disparity affecting black women","volume":"24","author":"Cote","year":"2015","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1038\/s41379-020-00695-5_bib3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3390\/cancers12030686","article-title":"Pathogenesis and clinical management of uterine serous carcinoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Cancers"},{"key":"10.1038\/s41379-020-00695-5_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/PGP.0000000000000235","article-title":"Clinical significance of positive pelvic washings in uterine papillary serous carcinoma confined to an endometrial polyp","volume":"35","author":"Hanley","year":"2016","journal-title":"Int J Gynecol Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/PGP.0b013e318273fc55","article-title":"Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study","volume":"32","author":"Semaan","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Getz","year":"2013","journal-title":"Nature"},{"key":"10.1038\/s41379-020-00695-5_bib7","first-page":"177","article-title":"p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis","volume":"150","author":"Tashiro","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib8","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"10.1038\/s41379-020-00695-5_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1038\/s41379-020-00695-5_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1038\/s41379-020-00695-5_bib11","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.1993.11.10.1936","article-title":"Clinical significance of HER-2\/neu oncogene amplification in primary breast cancer","volume":"11","author":"Seshadri","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib12","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s11605-012-1979-2","article-title":"Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer","volume":"16","author":"Chan","year":"2012","journal-title":"J Gastrointest Surg"},{"key":"10.1038\/s41379-020-00695-5_bib13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.5858\/arpa.2011-0168-RS","article-title":"HER2\/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications","volume":"136","author":"Hechtman","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/s41379-020-00695-5_bib14","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1349-7006.2012.02240.x","article-title":"Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma","volume":"103","author":"Togami","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1038\/s41379-020-00695-5_bib16","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib17","first-page":"14","article-title":"HER-2\/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization","volume":"18","author":"Odicino","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/s41379-020-00695-5_bib18","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/cts.12207","article-title":"HER2-positive endometrial cancer subtype carries poor prognosis","volume":"7","author":"Lapi\u0144ska-Szumczyk","year":"2014","journal-title":"Clin Transl Sci"},{"key":"10.1038\/s41379-020-00695-5_bib20","first-page":"5693","article-title":"Amplification and overexpression of HER-2\/neu (c-erbB2) in endometrial cancers: correlation with overall survival","volume":"55","author":"Saffari","year":"1995","journal-title":"Cancer Res"},{"key":"10.1038\/s41379-020-00695-5_bib21","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13000-016-0553-8","article-title":"Systematic assessment of HER2\/neu in gynecologic neoplasms, an institutional experience","volume":"11","author":"Woo","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib24","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/ijgc-00009577-200609000-00027","article-title":"HER-2\/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications","volume":"16","author":"Villella","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/s41379-020-00695-5_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2005.03.041","article-title":"Determination of HER2\/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization","volume":"98","author":"Santin","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/modpathol.3800006","article-title":"Analysis of HER-2\/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2\/neu, p53 and Ki-67 protein expression, and outcome","volume":"17","author":"Peir\u00f3","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4757-3147-7_4","article-title":"The molecular and cellular biology of HER2\/neu gene amplification\/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer","volume":"103","author":"Pegram","year":"2000","journal-title":"Cancer Treat Res"},{"key":"10.1038\/s41379-020-00695-5_bib28","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1172\/JCI57152","article-title":"Targeted therapies for breast cancer","volume":"121","author":"Higgins","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1038\/s41379-020-00695-5_bib29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-020-00695-5_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.critrevonc.2012.08.008","article-title":"Advanced HER2-positive gastric cancer: current and future targeted therapies","volume":"85","author":"Pazo Cid","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1038\/s41379-020-00695-5_bib32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1038\/s41379-020-00695-5_bib33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.gore.2016.12.003","article-title":"Regression of metastatic, radiation\/chemotherapy-resistant uterine serous carcinoma overexpressing HER2\/neu with trastuzumab emtansine (TDM-1)","volume":"19","author":"Santin","year":"2017","journal-title":"Gynecol Oncol Rep"},{"key":"10.1038\/s41379-020-00695-5_bib34","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1136\/ijgc-00009577-200605000-00064","article-title":"Use of trastuzumab in the treatment of metastatic endometrial cancer","volume":"16","author":"Jewell","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/s41379-020-00695-5_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib36","doi-asserted-by":"crossref","unstructured":"Santin AD. Letter to the Editor referring to the manuscript entitled: \u201cPhase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study\u201d recently reported by Fleming et al., (Gynecol Oncol., 116. Gynecol Oncol. 2010;118:95\u201396.","DOI":"10.1016\/j.ygyno.2010.01.043"},{"key":"10.1038\/s41379-020-00695-5_bib37","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase ii trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib38","unstructured":"National Comprehensive Cancer Network. Uterine neoplasms (Version 1.2020). 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf."},{"key":"10.1038\/s41379-020-00695-5_bib39","unstructured":"Fitzgibbons PL, Bartley AN, Longacre TA, Broaddus R, Chuang LT, Cohen MB, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the endometrium, v1.2.0.1. Northfield, Illinois: College of American Pathologists; 2019."},{"key":"10.1038\/s41379-020-00695-5_bib40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Le\u00f3n\u2010Castillo","year":"2020","journal-title":"J Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41379-018-0125-4","article-title":"Targeted next-generation sequencing in the detection of mismatch repair deficiency in endometrial cancers","volume":"32","author":"Dong","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib42","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/ College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib43","doi-asserted-by":"crossref","first-page":"e87062","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"10.1038\/s41379-020-00695-5_bib44","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/s41379-020-00695-5_bib45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/sim.1012","article-title":"Tests for equivalence or non-inferiority for paired binary data","volume":"21","author":"Liu","year":"2002","journal-title":"Stat Med"},{"key":"10.1038\/s41379-020-00695-5_bib46","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0197-2456(03)00025-4","article-title":"Matched-pair noninferiority trials using rate ratio: A comparison of current methods and sample size refinement","volume":"24","author":"Tang","year":"2003","journal-title":"Control Clin Trials"},{"key":"10.1038\/s41379-020-00695-5_bib47","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1038\/s41379-020-00695-5_bib48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2559.2009.03464.x","article-title":"HER-2\/neu receptor gene status in endometrial carcinomas: a tissue microarray study","volume":"56","author":"Xu","year":"2010","journal-title":"Histopathology"},{"key":"10.1038\/s41379-020-00695-5_bib49","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/PAS.0000000000000182","article-title":"HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas","volume":"38","author":"Mentrikoski","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib50","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1525-1438.2007.01181.x","article-title":"Serous carcinoma of the uterus-determination of HER-2\/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation","volume":"18","author":"Singh","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1038\/s41379-020-00695-5_bib51","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status","volume":"19","author":"Ross","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1038\/s41379-020-00695-5_bib52","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ajcp\/aqz031","article-title":"Detection of ERBB2 amplification by next-generation sequencing predicts HER2 expression in colorectal carcinoma","volume":"152","author":"Cenaj","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib53","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5858\/arpa.2012-0416-RA","article-title":"HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges","volume":"138","author":"Buza","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1038\/s41379-020-00695-5_bib54","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/s41379-020-0504-5","article-title":"Integrated genomic characterization of ERBB2\/HER2 alterations in invasive breast carcinoma: a focus on unusual FISH groups","volume":"33","author":"Yang","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib55","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1200\/JCO.18.00788","article-title":"Human epidermal growth factor receptor 2 testing by fluorescent in situ hybridization: positive or negative? ASCO\/College of American Pathologists guidelines 2007, 2013, and 2018","volume":"36","author":"Murray","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib56","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.18.00809","article-title":"Implementation of the 2018 human epidermal growth factor receptor 2 guidelines by ASCO\/College of American Pathologists will reduce false-positive tests","volume":"36","author":"Martin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2015.01.533","article-title":"HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant","volume":"137","author":"Growdon","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1038\/s41379-020-00695-5_bib58","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1524-4741.2007.00396.x","article-title":"Intratumoral heterogeneity of HER2\/neu in breast cancer? A rare event","volume":"13","author":"Hanna","year":"2007","journal-title":"Breast J"},{"key":"10.1038\/s41379-020-00695-5_bib59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jamcollsurg.2012.09.007","article-title":"Does breast tumor heterogeneity necessitate further immunohistochemical staining on surgical specimens?","volume":"216","author":"Greer","year":"2013","journal-title":"J Am Coll Surg"},{"key":"10.1038\/s41379-020-00695-5_bib60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2013.103","article-title":"HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity","volume":"27","author":"Hanna","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib61","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"key":"10.1038\/s41379-020-00695-5_bib62","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/PAI.0b013e31822c3a0f","article-title":"HER2 testing in gastric and gastroesophageal junction cancers","volume":"19","author":"Hicks","year":"2011","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-020-00695-5_bib63","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1038\/s41379-020-00695-5_bib64","first-page":"2199","article-title":"Heterogeneity of erbB-2 gene amplification in bladder cancer","volume":"53","author":"Sauter","year":"1993","journal-title":"Cancer Res"},{"key":"10.1038\/s41379-020-00695-5_bib65","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/modpathol.2012.125","article-title":"Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung","volume":"25","author":"Grob","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-020-00695-5_bib66","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/bjc.2017.422","article-title":"HER2 expression patterns in paired primary and metastatic endometrial cancer lesions","volume":"118","author":"Halle","year":"2018","journal-title":"Br J Cancer"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-00695-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-00695-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222006603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222006603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41379-020-00695-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:38:29Z","timestamp":1760229509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222006603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0893395222006603"],"URL":"https:\/\/doi.org\/10.1038\/s41379-020-00695-5","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-020-00695-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}